scholarly journals Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice

Hepatology ◽  
2011 ◽  
Vol 54 (3) ◽  
pp. 846-856 ◽  
Author(s):  
Andrew M. Miller ◽  
Hua Wang ◽  
Adeline Bertola ◽  
Ogyi Park ◽  
Norio Horiguchi ◽  
...  
Keyword(s):  
Fatty Liver ◽  
Interleukin 6 ◽  
Liver Diseases ◽  
Interleukin 10 ◽  
Signal Transducer ◽  
Nonalcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver Diseases ◽  
Transcription 3 ◽  
Deficient Mice

scholarly journals Green Tea and Epigallocatechin Gallate (EGCG) for the Management of Nonalcoholic Fatty Liver Diseases (NAFLD): Insights into the Role of Oxidative Stress and Antioxidant Mechanism

Antioxidants ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1076
Author(s):  
Guoyi Tang ◽  
Yu Xu ◽  
Cheng Zhang ◽  
Ning Wang ◽  
Huabin Li ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Fatty Liver ◽  
Green Tea ◽  
Liver Diseases ◽  
Randomized Clinical Trials ◽  
Epigallocatechin Gallate ◽  
Protective Effects ◽  
Nonalcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver Diseases ◽  
Underlying Mechanisms

Nonalcoholic fatty liver diseases (NAFLD) represent a set of liver disorders progressing from steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma, which induce huge burden to human health. Many pathophysiological factors are considered to influence NAFLD in a parallel pattern, involving insulin resistance, oxidative stress, lipotoxicity, mitochondrial dysfunction, endoplasmic reticulum stress, inflammatory cascades, fibrogenic reaction, etc. However, the underlying mechanisms, including those that induce NAFLD development, have not been fully understood. Specifically, oxidative stress, mainly mediated by excessive accumulation of reactive oxygen species, has participated in the multiple NAFLD-related signaling by serving as an accelerator. Ameliorating oxidative stress and maintaining redox homeostasis may be a promising approach for the management of NAFLD. Green tea is one of the most important dietary resources of natural antioxidants, above which epigallocatechin gallate (EGCG) notably contributes to its antioxidative action. Accumulative evidence from randomized clinical trials, systematic reviews, and meta-analysis has revealed the beneficial functions of green tea and EGCG in preventing and managing NAFLD, with acceptable safety in the patients. Abundant animal and cellular studies have demonstrated that green tea and EGCG may protect against NAFLD initiation and development by alleviating oxidative stress and the related metabolism dysfunction, inflammation, fibrosis, and tumorigenesis. The targeted signaling pathways may include, but are not limited to, NRF2, AMPK, SIRT1, NF-κB, TLR4/MYD88, TGF-β/SMAD, and PI3K/Akt/FoxO1, etc. In this review, we thoroughly discuss the oxidative stress-related mechanisms involved in NAFLD development, as well as summarize the protective effects and underlying mechanisms of green tea and EGCG against NAFLD.

Gut microbiota in nonalcoholic fatty liver diseases with and without type-2 diabetes mellitus

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Hamed Ebrahimzadeh Leylabadlo ◽  
Hossein Samadi Kafil ◽  
Safar Farajnia ◽  
Dariush Shanehbandi ◽  
Seyed Yaghoub Moaddab ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Liver Diseases ◽  
Nonalcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver Diseases

Turmeric Supplementation Improves Serum Glucose Indices and Leptin Levels in Patients with Nonalcoholic Fatty Liver Diseases

2017 ◽  
Vol 36 (4) ◽  
pp. 261-267 ◽  
Author(s):  
Roya Navekar ◽  
Maryam Rafraf ◽  
Aida Ghaffari ◽  
Mohammad Asghari-Jafarabadi ◽  
Manouchehr Khoshbaten
Keyword(s):  
Fatty Liver ◽  
Liver Diseases ◽  
Serum Glucose ◽  
Nonalcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver Diseases

scholarly journals The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

2003 ◽  
Vol 112 (1) ◽  
pp. 91-100 ◽  
Author(s):  
Aimin Xu ◽  
Yu Wang ◽  
Hussila Keshaw ◽  
Lance Yi Xu ◽  
Karen S.L. Lam ◽  
...  
Keyword(s):  
Fatty Liver ◽  
Liver Diseases ◽  
Nonalcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver Diseases

scholarly journals From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases

2020 ◽  
Vol 295 (34) ◽  
pp. 12279-12289 ◽  
Author(s):  
Peng Zhao ◽  
Alan R. Saltiel
Keyword(s):  
Protein Kinase ◽  
Liver Injury ◽  
Fatty Liver ◽  
Liver Diseases ◽  
Energy Status ◽  
Nonalcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver Diseases ◽  
Ampk Activity ◽  
Amp Activated Protein Kinase ◽  
The Impact

Nonalcoholic fatty liver diseases (NAFLDs), especially nonalcoholic steatohepatitis (NASH), have become a major cause of liver transplant and liver-associated death. However, the pathogenesis of NASH is still unclear. Currently, there is no FDA-approved medication to treat this devastating disease. AMP-activated protein kinase (AMPK) senses energy status and regulates metabolic processes to maintain homeostasis. The activity of AMPK is regulated by the availability of nutrients, such as carbohydrates, lipids, and amino acids. AMPK activity is increased by nutrient deprivation and inhibited by overnutrition, inflammation, and hypersecretion of certain anabolic hormones, such as insulin, during obesity. The repression of hepatic AMPK activity permits the transition from simple steatosis to hepatocellular death; thus, activation might ameliorate multiple aspects of NASH. Here we review the pathogenesis of NAFLD and the impact of AMPK activity state on hepatic steatosis, inflammation, liver injury, and fibrosis during the transition of NAFL to NASH and liver failure.

Demethyleneberberine decreases nonalcoholic fatty liver diseases in mice

2014 ◽  
Vol 6 (6) ◽  
pp. 741-742
Author(s):  
Xiaoyan Qiang ◽  
Lulu Xu ◽  
Pengcheng Zhang ◽  
Yubin Zhang
Keyword(s):  
Fatty Liver ◽  
Liver Diseases ◽  
Nonalcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver Diseases
Sign in / Sign up

Export Citation Format

Share Document